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Abstract  
Background: In North America and three European countries Translational Medicine (TM) 
funding has taken center stage as the National Institutes of Health (NIH), for example, has 
come to recognize that delays are common place in completing clinical trials based upon 
benchside advancements. Recently, there are several illustrative examples whereby the 
translation of research had untoward outcomes requiring immediate action.  
Methods: Focus more on three-dimensional (3D) simulation, biomarkers, and Artificial 
Intelligence may allow orthopaedic surgeons to predict the ideal practices before 
orthopaedic surgery. Using the best medical imaging techniques may improve the 
accuracy and precision of tumor resections.   
Results: This article is directed at the young surgeon scientist and in particular 
orthopaedic residents and all other junior physicians in training to help them better 
understand TM and position themselves in career paths and hospital systems that strive 
for optimal TM. It serves to hasten the movement of knowledge garnered from the 
benchside and move it quickly to the bedside.   
Conclusions: Communication is ongoing in a bidirectional format. It is anticipated that 
more and more medical Centers and institutions will adopt TM models of healthcare 
delivery.  
 Keywords: Translational Medicine; 3D simulation; Tumor bone, biomarkers, Artificial 
Intelligence   
 
 
     
1. Introduction  
Translational Medicine (TM) has received significant attention in the past decade and it is still a 
buzzword in the medical field today. Given the growing impact of scientific discoveries, 
translational medicine was initially described as the 'marriage' between basic science and clinical 
science which represents a tremendous challenge [1,2,3,4]. What defines TM? According to the 
European Society for Translational Medicine (EUSTM) TM consists of 3 pillars: the scientist at 
his/her benchside; the clinician at the bedside; and the community at large, which includes the 
drivers of medical advancements such as non-profit foundations, government funded 
universities and corporations providing medical services devices or medications within house 
research and development (RD) divisions. The interaction between the 3 pillars is bidirectional 
(''bench to bedside'' and  ''bedside to bench to bedside''). The main objective of translational 
research from ''bench to bedside'' is to test in human novel discoveries. Based on basic science 
such as mathematics, physics, biology and chemistry, we can produce new drugs, devices and 
treatments for patients. Sometimes, our understanding of many human diseases, such as 
hypertension is very limited.  For that purpose, there is a critical need for ''bedside to bench to 
bedside''. Ernesto et al. [5] give an excellent example of bedside to bench to bedside. The authors 
explain the role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in 
hypertension. To conclude, the global objective of TM is to advance local or regional med-surg 
care swiftly successfully, and repeatedly and then apply these methods on a broader scale to 
improve sovereign, national and  
eventually global healthcare. All of this is in direct contrast to traditional academic centers with 
laboratories and professors working independently within their own discipline with little to no 
communication with other scientists. The best possible description of this separatism 
arrangement is the proverbial silo effect or isolation.   
2. Obstacles to Translational Medicine  
Many challenges face scientists to apply translational research, including lack of sufficient funding, 
high cost and slow results, and lack of congressional and public support [6,7,8,9,10]. In the case 
of the bench-to-bedside direction, the complexity of translational research in human subjects is 
overwhelming: production and validation of products of consistent safety, potency and quality, 
the ancillary needs associated with the care of patients with severe conditions and the cost of 
validating translatable biomarkers renders this discipline uniquely expensive. How can small or 
medium biotechnology firms justify these costs? Similarly, how can academic institutions seeking 
to translate ideas of their research faculty take the economical risk of supporting a promising 
clinical trial? Most translational research is supported by grants; however, few provide funding 
for regulatory staff or consultation. Academic institutions do not provide support to non 
hypothesis driven research such as product development. Translational researchers need special 
training in the complexity of new technologies. Dual-trained physician-scientists are too few. For 
that purpose we need to focus on the development of scientific training programs for clinicians 
[11, 41]. Academic physicians in training should spend time in the laboratory and consider 
graduate courses or seminars that update and deepen their understanding of current research 
[46]. The purpose of these initiatives is not to increase the number of individuals who are fully 
trained in biology, math, medicine, statistics, etc [12].  
3. Mediouni-Model (T-model): What does it involve?  
In literature, many models have been used to improve the practice of surgeons in the operating 
room, such as Gawande [13], Howell [14], Miller [15] and Sadideen [16]. In 2019, Mediouni 
proposed a T-model that aims to bridges the gap between basic science and clinical sciences [17] 
(figure 1). The success of this model is based on multidisciplinary teams, which are involved in 
translational orthopaedics. Collaboration among disciplines through multidisciplinary teams 
facilitates the emergence of novel concepts. For example, the surgeon who works on bone tissue 
regeneration will participate in the activities of a clinical orthopedic surgery program and will 
discuss techniques of molecular biology or genetics. Based on those activities, surgeons will learn 
thinking skills, which help her/him to criticize new practices.  
 
 
Figure 1. Mediouni Model or (T-model). 
 
A deeper understanding of the cellular and molecular mechanisms that mediates bone formation 
can accelerate the treatment of complicated operation. For example, skeleton is one of the most 
structure in our body. Understanding more the microarchitecture can improve the treatment of 
osteoporosis which represents a global health problem.  
This new strategy can accelerate the development of artificial joints and limbs to relieve pain and 
improve quality of life, It can help the treatment of injuries arising from accidents or sporting 
activities.  
Translational orthopaedic is suitable for projects that build on orthopaedic science to develop 
therapies that may reach the clinical stage. These projects are intended to create the value of the 
associated intellectual property through activities such as prototype development and testing for 
proof of concept.  
  
4. The Role of Three-Dimensional (3D) Simulation in Orthopaedic practice  
New approaches simulation are emerging that bring computer science, physics, chemistry and 
engineering. To radically improve our understanding of medical devices, simulation offers many 
benefits for designing and understanding mechanical behaviour of devices. There are several key 
design and simulation approaches available to researchers, engineers, and analysts, including 
Computer-Aided Design (CAD). Finite Element Analysis (FEA) [18, 19] is a numerical method 
which can calculates stresses and forces during the contact between structures. Using FEA, to 
avoid the problems of osteonecrosis, we can measure the temperature by estimating the 
parameters during drilling such as: speed of drill bit, feed rates, forces applied by the users (see 
figure 2) [20].   
 
 
Figure 2: (a) 3D simulation of drilling of acetabular bone,  (b) A pelvic model and FEA defined 
variables to reduce heat generation and its consequence (threshold is 50°C), bone necrosis. The 
FEA data has two never before reported findings. (1) When drilling 3 mm of cortical bone at a 
constant rotation of 600 rev/min. feeding 1 mm/sec produces a force of 50-80 Newton (N) and 
75°C temperature, and (2) Reducing the feeding speed to 0.1 mm/sec, the temperature is 
reduced to 39°C, with constant axial force and rotation of 600 rev/min. Extracted from [20].  
 
Computational Fluid Dynamics (CFD) [21] is another branch that allows one to simulate fluid 
motion using numerical approaches. CFD may address many challenges and answers for example 
the question: What is the best volume of water at room temperature to minimize bone cell death 
by keeping the metal drill bit temperature low? In the literature, there is no application in 
orthopaedics which combine CFD and FEA. Acquiring three-dimensional (3D) imaging data from 
medical images magnetic resonance imaging (MRI) and Computed Tomography (CT) provides a 
basis for creating anatomical models of human anatomy. The 3D model image data are used in 
many applications, including analyzing implant stability and tissue stress. Many challenges faced 
orthopaedic simulation in order to reproduce the complex structures include technical 
competences, consistency between results, and validation. Being able use the simulator for 
training can help surgeons to improve their practice. Frankly, simulation does not replace 
experimental testing, but provides a fast-evolving option for validation and evaluation.  
  
5. The Role of Imaging for TM in Bone Tumors  
Cancer is responsible for the death of many people around the world [44]. A large percentage of 
patients die after developing cancer despite aggressive treatment. There is a great need for new 
approaches to cancer therapy. Genomic and protein technology have generated a huge amount 
of essential information to broaden our understanding of cancer biology. New research has 
paved the way for drug development targeting biological and specific models. Introduction of 
imatinib into the clinic took forty years beyond the discovery of the Philadelphia chromosome 
[22]. Trastuzumab was not clinically available for another twenty years and faced considerable 
difficulties throughout its development and testing process. A possible explanation of the gap 
between clinical and preclinical results is the interaction between targeted molecular therapy 
and cytotoxic targeting the same tumor cell. The main goal of translational research is to design 
the best methods and strategies that allow for high efficiency. The development of new images 
techniques can have a major impact on the practice of oncology. Quantitative dynamic-contrast 
magnetic resonance (MR) imaging is a non-invasive technique that estimates the percentage of 
necrosis in bone tumors and post-treatment modification [23]. It incorporates two approaches 
for the acquisition of dynamic MR images such as DCE-MR imaging use T1-weighted acquisitions, 
while susceptibility based techniques such as dynamic susceptibility contrast-enhanced MR 
imaging (DSC-MR imaging) use T2-based sequences [24].   
Diffusion Weighted Imaging (DWI) [25] is generally used to visualize areas of tissue in which a 
pathological process has altered the movement of fluid that is outside the vessels. Water 
diffusion is more limited in the tumor region than in normal tissues. This information can 
represent a high signal intensity. Today, the progression of molecular imaging allows clinicians to 
understand tumor biology better. For  
example, optical imaging [26] is based on light emission following enzymatic reaction of 
luciferase which is used to see the tumor's progression (see figure 3). Magnetic resonance 
spectroscopy (MRS) [27] is another modality which has advantages compared to other modalities, 
including the improvement of signal/noise ratio, spatial resolution and the possibility to obtain 
anatomical and physiological information. It allows measurement of the quantity of metabolites 
which can reflect molecular composition of tumor.   
 
Today, several combination strategies are used in translational studies. Combinations include: 
MRI/optical imaging, nuclear imaging / optical imaging, and Nuclear imaging/ MRI. By combining 
different modalities, additive information can be used to evaluate the progression of the tumors 
compared to using a single imaging modality alone  [28]. However, the clinical translation of these 
combinations system could be difficult. The integrated system design for preclinical and clinical 
scanners should be significant. A better understanding of cancer gene as well as the growing 
superiority of imaging technologies helps crucial researchers and clinicians in translating the 
disease.  
 
 
Figure 3. Multimodality imaging of Balb/C athymic nude mouse bearing human MCF7 tumor 
xenograft [26]. 
 
 
6. Biomarkers to improve orthopaedic results  
  
Biomarkers open new perspectives for diagnosis. That they are genetic, physiological and 
detectable in the blood, biopsy, or imaging, measurable biological features, called biomarkers, 
act as indicators of the onset of disease or susceptibility to certain conditions. Advances in genetic, 
protein and cellular analysis techniques, especially since the sequencing of the human genome 
in 2003, encourage researchers to analyze the mechanisms underlying the development of a 
disease. It is then necessary to identify the variations that will make it possible to distinguish the 
healthy individual from the patient. In other words, we are looking for potential biomarkers, 
heralding an orthopaedic problem. We can cite the role of biomarkers in the diagnostic of 
periprosthetic joint infection (PJI). The diagnostic of PJI is very difficult and the clinicians have to 
use a combination of tests that are not accurate [29]. In literature, several molecular biomarkers 
aimed to analyze the current diagnostic measures for PJI such as serum biomarkers [30] and 
Synovial fluid biomarkers [31]. The study of [32] shown that serum markers namely CRP and ESR, 
are elevated with any type of inflammation and infection, compromising their specificity for the 
diagnosis of PJI. Synovial fluid biomarkers play a very important role in the diagnosis of PJI. When 
infection occurs in a joint, cytokines such as IL-1b, IL-6, IL-8, IL-17, and TNF-α are released from 
macrophages. The biomarkers can identify Prei-Implant Osteolysis before radiographic diagnosis 
[33]. It can differentiate patients who developed osteolysis from those who did not develop 
osteolysis before radiographic diagnosis. Today, Osteoarthritis (OA) is the most common disease 
affecting the joints in humans and is an important cause of pain, disability [34, 35, 36]. New 
information and studies in equine musculoskeletal biomarkers have potential translational value 
for humans and vice versa. McIlwraith et al. [37] explain the biomarkers for equine joint injury 
and osteoarthritis. In osteosarcoma, the biology of malignant progression is still unknown. 
Therefore, protein and gene expression studies have been used to provide to obtain clues about 
the causes of osteosarcomas. The identification of tumor-specific biomarkers and therapeutic 
targets is the most important challenge to understand and to predict osteosarcoma [38, 39, 40].  
 
7. Application of Artificial Intelligence in orthopaedics   
Recently, artificial intelligence (AI) has become more widespread and it’s use in medical and 
orthopaedic applications has been increasing. A recent review of AI in orthopaedics (Panchmatia 
et al., 2018) [41] summarised that AI in orthopaedics can improve patient care in four key areas: 
(i) diagnosis, (ii) management, (iii) research and (iv) systems analysis. Specific examples of AI in 
orthopaedics include personalizing patient care and also enabling high-quality orthopaedic care 
even within lower resource settings, for example by increasing research capacity within 
institutions.   
Developing efficient and effective AI solutions to apply within orthopaedic disciplines requires 
multidisciplinary inputs. The AI cannot be developed by computer scientists in isolation but 
requires ongoing and active input from clinicians. Involving orthopaedic consultants in 
development of AI ensures achieving maximum benefit for patients [42] and will take into 
account all necessary health and safety, ethical, governance, legal regulation, and health service 
management considerations  
One area in which AI is impacting to benefit orthopaedic practice is for fracture detection, which 
incorporates AI algorithms into the medical image analysis (Langerhuizen et al., 2019) [43]. 
Various clinical studies have investigated this emerging area of orthopaedic AI. Fracture detection 
and fracture classification has been applied to many bones including spine, wrist, ankle, hand, 
hip, ulna, diaphyseal femur, and proximal humerus [43] producing near perfect prediction (range, 
0.95- 
1.0) which could potentially outperform human experts.  
Currently, AI has shown benefit in challenging diagnostic and therapeutic orthopaedic scenarios. 
Moving forward, standardized methods to train and test AI are required to enable further 
integration within clinical workflows. The decision making capabilities of AI has been fuelled by 
growing availability of large datasets, innovative algorithms, and increased storage capacity and 
lower costs of high computational power. In orthopaedics, AI provides value for health services 
and relieve time pressures, by lowering reliance on expert consultants, by enabling (i) advanced 
data discovery extraction (ii) improved predictive and diagnostic capabilities, and (iii) AI driven 
orthopaedic decision support systems.  
 
8. Discussion and conclusions  
Working fluently, clinical results could be improved with more awareness concerning the applied 
and translational characteristics of basic research. Today, we need a new generation of 
researchers: '' translational scientists'' who can play a necessary part in coordination the different 
field of research. Elias Zerhouni, the director of the NIH (2002-2008) is an example of the type 
scientist that we need, he convened a series of whirlwind meetings with top clinicians and 
scientists. He has a unique perspective on the complex process of bringing drugs to clinical 
applications (see figure 4). The Senior author MM propose Mediouni model or (T-model) in which 
the communication between surgeons with other scientists in many fields has many benefits in 
terms of understanding a solutions for complex clinical problems.  
 
 
Figure 4. Dr. Elias Zerhouni, director of the National Institutes of Health (2002-2008) published 
a roadmap for NIH on Science, clarifying that translational medicine would be a core and 
mainstream of researches in the future [45]. 
 
 
In conclusion, this review discloses the beneficial educational impacts of 3D simulation and 
biomarkers which can increase the authenticity of learning, and also the learner’s anatomical 
understanding of a disease process such as bone tumors. We can connect the orthopaedic dots 
better by understanding and adopting the TM models established elsewhere as discussed 
previously. In addition one could initiate their own TM community in most city and town regions, 
since colleges and universities are fairly numerous and open to collaborations with progressive 
clinicians (see illustrations presented earlier in this article). Partnerships can be  
established with local orthopaedic residency programs possibly as well as businesses and 
orthopedic companies. The local sales representatives can often connect surgeons with their 
respective R&D personnel. 
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